Eudragit RS100 nanosuspensions for the ophthalmic controlled delivery of ibuprofen.
about
Transformation of eutectic emulsion to nanosuspension fabricating with solvent evaporation and ultrasonication technique.Preparation, characterization and in vitro release properties of ibuprofen-loaded microspheres based on polylactide, poly(epsilon-caprolactone) and their copolymers.Cyclosporine a-nanosuspension: formulation, characterization and in vivo comparison with a marketed formulation.Poly[LA-(Glc-Leu)] copolymer as a carrier for ocular delivery of ciprofloxacin: formulation, characterization and in vivo biocompatibility study.Development of an enhanced formulation for delivering sustained release of buprenorphine hydrochloride.Conjugation of cell-penetrating peptides with poly(lactic-co-glycolic acid)-polyethylene glycol nanoparticles improves ocular drug deliveryPrednisolone-loaded nanocapsules as ocular drug delivery system: development, in vitro drug release and eye toxicity.Nanotechnology in oncology: Characterization and in vitro release kinetics of cisplatin-loaded albumin nanoparticles: Implications in anticancer drug delivery.Nanosuspensions: a promising drug delivery strategy.Cationic vectors in ocular drug delivery.PLGA nanoparticles for ocular delivery of loteprednol etabonate: a corneal penetration study.Downregulation of VEGF mRNA expression by triamcinolone acetonide acetate-loaded chitosan derivative nanoparticles in human retinal pigment epithelial cells.Improvement of Oral Bioavailability of Curcumin upon Microencapsulation with Methacrylic Copolymers.Ocular drug delivery: nanomedicine applications.Nanoparticles in modern medicine: state of the art and future challenges.Topical ocular delivery of NSAIDs.Toxicity of nanomaterials to the eye.Molecularly imprinted therapeutic contact lenses.Feasibility of lipid nanoparticles for ocular delivery of anti-inflammatory drugs.Ocular application of chitosan.Novel strategies for anterior segment ocular drug delivery.Nanocrystals for the parenteral delivery of poorly water-soluble drugsNanoparticles laden in situ gelling system for ocular drug targeting.Impacts of nanomedicines in ocular pharmacotherapyChallenges and solutions in topical ocular drug-delivery systems.Topical delivery of ocular therapeutics: carrier systems and physical methods.Nanocarriers for ocular delivery for possible benefits in the treatment of anterior uveitis: focus on current paradigms and future directions.Particles from preformed polymers as carriers for drug delivery.Preparation, characterization and biocompatibility studies of thermoresponsive eyedrops based on the combination of nanostructured lipid carriers (NLC) and the polymer Pluronic F-127 for controlled delivery of ibuprofen.Safety and toxicity of nanomaterials for ocular drug delivery applications.Uptake of Eudragit Retard L (Eudragit® RL) Nanoparticles by Human THP-1 Cell Line and Its Effects on Hematology and Erythrocyte Damage in Rats.Nanoparticles for drug delivery to the anterior segment of the eye.Formulation and corneal permeation of ketorolac tromethamine-loaded chitosan nanoparticles.Preparation of solid dispersions of nonsteroidal anti-inflammatory drugs with acrylic polymers and studies on mechanisms of drug-polymer interactions.Effect of water-in-oil microemulsions and lamellar liquid crystalline systems on the precorneal tear film of albino New Zealand rabbits.Comparison of Different Nanosuspensions as Potential Ophthalmic Delivery Systems for Ketotifen Fumarate.Ocular drug delivery: a clue from nanotechnology.Understanding the structure and stability of paclitaxel nanocrystalsDesign of eudragit RL nanoparticles by nanoemulsion method as carriers for ophthalmic drug delivery of ketotifen fumaratePreparation and In Vitro/Ex Vivo Evaluation of Moxifloxacin-Loaded PLGA Nanosuspensions for Ophthalmic Application.
P2860
Q30380599-F81794AB-1983-448A-983A-903F4D88B4F1Q33219523-FFF38BBE-A139-470B-BD86-06BFDD2E8C03Q34409932-BD8A5B30-F61C-44AF-BB7F-F5F28B817E02Q34707455-3E5CE848-E1BC-4E3F-B5A7-8A9323ED80F1Q34957716-4D1094FE-C1CA-41FF-9058-31C2DA53D46EQ35043797-6F44D37D-7142-4E37-ADFF-F906AC6668E4Q35138918-F43C9173-EDA9-4D8A-A2D1-48AB4A6A2915Q35157105-B7D9CB36-5421-4C63-9B90-D5DC203ECBFDQ35826447-106FD9F9-B959-4608-B6F3-6F6C4785A1F6Q35994783-D8716AEE-A39C-42B0-89FF-D6D1FA2226D0Q36070388-7CF28BC0-7295-4C2A-B64B-5EA72D4E904FQ36191344-55969145-9CDE-4BA6-BCBE-37CBD2418D86Q36244041-7122CCC5-500B-4324-B547-80C2CE7DFB2CQ36918036-A31FD91C-000D-42B4-9DB9-B5F4E11BFE62Q36920457-20A7D0DA-C12F-48A6-AEB8-A1557BFCB9BBQ37147923-F03C622D-373A-4CF1-A547-6721F3CDE412Q37676123-000C2099-E542-4F35-A3C5-5DCD6B105E4CQ37735178-8BCE3169-8E3A-40B4-96B0-FAAE5537B7DBQ37769529-C2F050A1-978E-4007-8C8C-36601863915CQ38005199-2429796E-7166-462A-A930-06EEF158B1E5Q38065184-CC420C17-92B5-4B58-B346-FA2B314AD0C1Q38104343-A1E263F2-D75C-4998-A187-C8816E0ADADCQ38105564-AED4777A-53FE-4D7F-BE96-CA16D664A595Q38107200-77A7D4F8-CFB6-4858-BD68-4D76DFF48502Q38177335-155D7F2F-608A-4997-A9C3-5F35F39C0F85Q38196446-202D1BB6-D7EB-4D4A-9A74-7145BC0F1269Q38227621-B50F338F-2DD1-4291-9243-6A58CF766EBCQ38594961-63C0E27C-56F1-442D-B16F-416C46F7B086Q38714705-2FF2CE32-CE90-424C-8347-B48C4C1CE716Q38793489-3D1D519D-FFAA-4CF7-A756-9800D609349EQ39020781-1BCF376A-F201-42C1-BC3D-D0F37E72CA4FQ39230212-F30A2C77-392F-4B04-A99C-743FFFC1F24BQ40500729-ECFEBEE9-58BF-4930-802C-D18C61E5B99DQ40568609-7CAD33F9-0018-4572-A00D-61927087B3A5Q41352812-1C336036-8B2F-421A-A2D3-18150344346EQ41513479-B0B8504E-FDC8-4D2A-BE7E-0188A815CAFEQ41568973-023C2087-7FFA-4AF8-8716-BB997C184E9BQ41884506-1F3B547E-88CF-4AEF-A19C-7FE8DAD16D6CQ42110933-ABCD8E8A-23E5-4F98-B9A0-C7A01FC3B535Q42131745-1163B1A0-4FA9-4222-9604-CBDFFB5CA3D9
P2860
Eudragit RS100 nanosuspensions for the ophthalmic controlled delivery of ibuprofen.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh
2002年學術文章
@zh-hant
name
Eudragit RS100 nanosuspensions for the ophthalmic controlled delivery of ibuprofen.
@en
Eudragit RS100 nanosuspensions for the ophthalmic controlled delivery of ibuprofen.
@nl
type
label
Eudragit RS100 nanosuspensions for the ophthalmic controlled delivery of ibuprofen.
@en
Eudragit RS100 nanosuspensions for the ophthalmic controlled delivery of ibuprofen.
@nl
prefLabel
Eudragit RS100 nanosuspensions for the ophthalmic controlled delivery of ibuprofen.
@en
Eudragit RS100 nanosuspensions for the ophthalmic controlled delivery of ibuprofen.
@nl
P2093
P1476
Eudragit RS100 nanosuspensions for the ophthalmic controlled delivery of ibuprofen.
@en
P2093
Adriana Maltese
Antonina Puleo
Giovanni Puglisi
Piera Ferrara
P356
10.1016/S0928-0987(02)00057-X
P407
P577
2002-07-01T00:00:00Z